Videos

Cyrus M. Khan, discusses the current use of PI3K inhibitors to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and how recent ODAC decisions impacted their use.

Craig Horbinski, MD, PhD, discusses the classification of gliomas based on histology and molecular features.

Dennis J. Slamon, MD, discusses the rationale of the phase 3 NATALEE trial and ribociclib for the treatment of patients with HR+/HER2- early breast cancer.

Rohan Garje, MD, discusses the goals of his research in assessing the outcomes of sarcomatoid vs classic urothelial carcinoma of bladder.

Ashwin Kishtagari, MD, discusses the PERSIST-2 trial of pacritinib for patients with primary myelofibrosis and low platelet counts.

Dr Amy Dezern discusses the criteria for subtype classification and risk stratification in patients with MDS.

Amy Dezern, MD, MHS, shares the case of a 70-year-old man with MDS stratified as low-risk using the Revised International Prognostic Scoring System.

Lisa B. Ercolano, MD, discusses the treatment of sarcomas in an era of molecular medicine.

Dr Elizabeth Davis presents the case of a young woman with a TSC2-mutated uterine PEComa.

Andrew Wagner, MD, PhD, details his typical treatment approach for systemic therapy in patients with malignant PEComa.

Lori Muffly, MD, discusses findings a sub-analysis of a phase 1 study investigating briquilimab with low-dose total body radiation and fludarabine.

In the first installment of this series, Elias Jabbour, MD, provides an overview of myelodysplastic syndrome, discusses the current treatment landscape for lower-risk MDS, and offers insights on factors that influence treatment selection.

Dr Savona and Dr. Zeidan define lower- vs higher-risk MDS, describe their approach to risk stratification, and share how assessing risk is critical for developing treatment plans for patients.

Michael Savona, MD and Amer Zeidan, MBBS review the biology underlying myelodysplastic syndrome and explain the patient journey from symptom presentation to official diagnosis.

Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.

A panel of experts discusses the types of graft versus host disease and the biologic pathways that are thought to be involved.

Dr Amer Zeidan explains the criteria he uses to assess risk in MDS, and why it is important to initiate treatment for lower-risk patients early.

Amer Zeidan, MBBS, discusses the signs and symptoms of lower-risk MDS and the tests typically used for diagnosis.

Jennifer R. Brown, MD, PhD, highlights the results from the phase 3 ALPINE study evaluating the treatment with zanubrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Samer A. Srour, MD, discusses the results of the phase 1 TRAVERSE trial of ALLO-316 in patients with advanced renal cell carcinoma.

Benjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Focused discussion on the first-line treatment armamentarium available to patients diagnosed with chronic lymphocytic leukemia.

Expert Andrew Lipsky, MD, reviews a patient case of relapsed/refractory chronic lymphocytic leukemia managed with BTK inhibition in the second-line setting.

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Eric Singer, MD, discusses the relevant data that led to the approval of sunitinib in the adjuvant treatment setting for renal cell carcinoma.

Elizabeth Davis, MD, explains the current treatment options available for patients with PEComa.

Andrew Folpe, MD, provides an overview of PEComas, including their incidence rate and malignant tumors.

Hatem Soliman, MD, discusses fam-trastuzumab deruxtecan-nxki and its importance for patients with HER2-positive breast cancer.

Karim Fizazi, MD, discusses the toxicities seen with the combination of talazoparib plus enzalutamide.

Warren Swegal, MD, explains how lenvatinib in currently used in the differentiated thyroid cancer landscape.